NCS Multistage posted Q2 2026 revenue of $38.4 million, up 5% year over year.
Net results swung to a loss of $4.6 million, or $(1.71) per share, from a profit a year earlier.
Adjusted EBITDA (non-GAAP) slipped to $1.9 million from $2.2 million.
Cash totaled $31.3 million at June 30, 2026; total debt was $7.5 million, consisting entirely of finance lease obligations.
CEO Ryan Hummer cited revenue growth led by Repeat Precision and U.S. tracer diagnostics, while the Weatherford deal remains expected to close in H2 2026.
NCSM•
